Intelligence Feed event · Policy · 2026-10-01

    Theriva Biologics Publishes Phase 2b VIRAGE data in Nature Medicine.

    Question

    Theriva Biologics Publishes Phase 2b VIRAGE data in Nature Medicine.

    Direct answer

    Theriva Biologics has published clinical findings from its Phase 2b VIRAGE study in Nature Medicine, presenting peer-reviewed evidence for its oncolytic adenovirus candidate VCN-01 (zabilugene almadenorepvec) in metastatic pancreatic ductal adenocarcinoma. The clinical dataset demonstrated statistically meaningful improvements in overall survival (OS), progression-free survival (PFS), and duration of response when VCN-01 was combined with standard-of-care chemotherapy. Publication in a top-tier medical journal provides external validation for the mechanism.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-01
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Theriva Biologics Publishes Phase 2b VIRAGE data in Nature Medicine.”, revision 1, evidence through 2026-10-01. https://marketontology.com/market-events/2026-10-01/theriva-biologics-publishes-phase-2b-virage-data-in-nature-medicine-c98b6b

    POLICY
    Theriva Biologics Publishes Phase 2b VIRAGE data in Nature Medicine.
    Theriva Biologics has published clinical findings from its Phase 2b VIRAGE study in Nature Medicine, presenting peer-reviewed evidence for its oncolytic adenovirus candidate VCN-01 (zabilugene almadenorepvec) in metastatic pancreatic ductal adenocarcinoma. The clinical dataset demonstrated statistically meaningful improvements in overall survival (OS), progression-free survival (PFS), and duration of response when VCN-01 was combined with standard-of-care chemotherapy. Publication in a top-tier medical journal provides external validation for the mechanism.
    TOVX
    Impact
    67
    OCT 1
    SIG
    88%
    TOVX
    Theriva Biologics Publishes Phase 2b VIRAGE data in Nature Medicine.
    Theriva Biologics has published clinical findings from its Phase 2b VIRAGE study in Nature Medicine, presenting peer-reviewed evidence for its oncolytic adenovirus candidate VCN-01 (zabilugene almadenorepvec) in metastatic pancreatic ductal adenocarcinoma. The clinical dataset demonstrated statistically meaningful improvements in overall survival (OS), progression-free survival (PFS), and duration of response when VCN-01 was combined with standard-of-care chemotherapy. Publication in a top-tier medical journal provides external validation for the mechanism.
    → Peer-reviewed Phase 2b survival efficacy in Nature Medicine de-risks regulatory approval pathways and clinical partnering valuations for oncology pipeline assets.
    Impact
    Theriva Biologics has published clinical findings from its Phase 2b VIRAGE study in Nature Medicine, presenting peer-reviewed evidence for its oncolytic adenovirus candidate VCN-01 (zabilugene almadenorepvec) in metastatic pancreatic ductal adenocarcinoma. The clinical dataset demonstrated statistically meaningful improvements in overall survival (OS), progression-free survival (PFS), and duration of response when VCN-01 was combined with standard-of-care chemotherapy. Publication in a top-tier medical journal provides external validation for the mechanism.
    Affected
    TOVX
    Transmission
    Peer-reviewed Phase 2b survival efficacy in Nature Medicine de-risks regulatory approval pathways and clinical partnering valuations for oncology pipeline assets.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    TOVXclinical pipeline de-risking and potential partnership valuation expansionUp1-5dPublication of positive Phase 2b survival data in Nature Medicine validates VCN-01 oncology platform.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month